OSAKA, Japan & CAMBRIDGE, Mass. - Monday, 14. September 2026
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill
Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis
The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027
(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3
Addressing unmet needs in psoriasis treatment
“Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zasocitinib has the potential to be a leading oral treatment option in psoriasis.”
Phase 3 clinical data supporting the zasocitinib NDA for moderate-to-severe plaque psoriasis
The NDA filing is supported by a comprehensive data package including the pivotal global Phase 3 LATITUDE PsO 3001 (NCT06088043) and 3002 (NCT06108544) studies, in which all primary and ranked secondary endpoints were met.1-2 The submission also included supportive data from LATITUDE PsO 3003 (NCT06550076), an open-label study to evaluate zasocitinib's long-term safety, tolerability and efficacy.4 Zasocitinib data demonstrated:1-2
Statistically significant and clinically meaningful improvements across multiple measures of skin clearance and symptom relief, with about 70% of patients achieving clear or almost clear skin (sPGA 0/1) at week 16.
Rapid and durable skin clearance for the majority of patients, with clearance observed as early as week 4 and increasing through week 24 and further through week 52.
High levels of skin clearance across hard-to-treat and high-impact sites, including the scalp, nails, palms and soles, which can result in reduced quality of life for patients.5
Zasocitinib was generally well tolerated, with a safety profile consistent with previous studies. No new safety signals were identified.
Next steps for zasocitinib
The European Medicines Agency (EMA) also accepted Takeda’s new marketing authorization application (MAA) for zasocitinib, initiating the review process for the treatment of moderate-to-severe plaque psoriasis. Takeda plans to submit additional applications for plaque psoriasis with global regulatory authorities to bring zasocitinib to people living with psoriasis worldwide.
The NDA filing has no significant impact on the full year consolidated financial forecast for the fiscal year ending March 31, 2027.
Q&A:
What specific data supports the zasocitinib FDA acceptance?
The NDA filing is supported by the pivotal Phase 3 LATITUDE PsO 3001 (NCT06088043) and 3002 (NCT06108544) studies, in which the co-primary and all 44 ranked secondary endpoints were met.1-2,6-7 The studies are global, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies to evaluate the efficacy, safety and tolerability of zasocitinib in adult patients with moderate-to-severe plaque psoriasis.6-7 Co-primary and select secondary endpoints at week 16 included:1-2
Co-primary Endpoints and Select Secondary Endpoints at Week 16
LATITUDE PsO 3001 Results
LATITUDE PsO 3002 Results
static Physician Global Assessment (sPGA) 0/1
71% zasocitinib vs 11% placebo and 32% apremilast (p<0.001)
69% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)
Psoriasis Area and Severity Index (PASI) 75
76% zasocitinib vs 12% placebo and 37% apremilast (p<0.001)
71% zasocitinib vs 12% placebo and 33% apremilast (p<0.001)
Select Secondary
Endpoints at Week 16
PASI 90
61% zasocitinib vs 5% placebo and 17% apremilast (p<0.001)
52% zasocitinib vs 4% placebo and 16% apremilast (p<0.001)
sPGA 0
40% zasocitinib vs 0.7% placebo and 8% apremilast (p<0.001)
34% zasocitinib vs 1% placebo and 7% apremilast (p<0.001)
PASI 100
33% zasocitinib vs 0.7% placebo and 3% apremilast (p<0.001)
25% zasocitinib vs 1% placebo and 4% apremilast (p<0.001)
Scalp-specific PGA (ssPGA) 0/1
77% zasocitinib vs 7% placebo and 42% apremilast (p<0.001)
74% zasocitinib vs 13% placebo and 30% apremilast (p<0.001)
Nail Psoriasis Severity Index (NAPSI), Least-squares mean change from baseline
-7.1 zasocitinib vs 1.8 placebo (p<0.001)
-8.6 zasocitinib vs -1.4 placebo (p<0.001)
Palmoplantar (hands and/or feet response) PGA (hfPGA) 0/1*
71% zasocitinib vs 22% placebo and 44% apremilast*
69% zasocitinib vs 10% placebo and 43% apremilast*
PASI 75 at Week 4
N/A
17% zasocitinib vs 4% for placebo (p<0.001)
Most Common Adverse Events (≥5%)
Upper respiratory tract infection (10.1%), nasopharyngitis (6.2%) and acne (6.5%), with no new safety signals identified**
*Not a multiplicity controlled secondary endpoint. Comparisons with apremilast are descriptive and should be interpreted accordingly.
**Sample size adjusted incidence proportion across the two studies.
When could zasocitinib become available to patients?
Zasocitinib is currently under FDA Priority Review, with a decision anticipated in the first quarter of 2027. If approved, zasocitinib could become available to appropriate patients after FDA approval.
About Plaque Psoriasis
Psoriasis is a chronic, systemic immune-mediated inflammatory disease characterized by itchy, painful, disfiguring and disabling skin lesions that impact one’s physical, emotional and psychological wellbeing.7,8,14 Globally, an estimated 66.4 million people are living with psoriasis, and about 80-90% of those have plaque psoriasis.15-17 Persistent itch, the appearance and location of skin lesions — especially in highly visible or high-impact sites — and related comorbidities, like psoriatic arthritis, play a major role in reducing quality of life and can lead to significant impacts on daily living.8,12-14 Psoriasis is also a heterogeneous disease driven by complex, interconnected immune pathways, genetics and environmental factors that differ across patients and over time, leading to variability in disease course, symptoms and treatment response.18-22
About Zasocitinib (TAK-279)
Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways.23-27 It has the potential to be a leading oral treatment option for people living with psoriasis that may deliver rapid and durable skin clearance in a convenient once-daily pill.1-2 Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data.23-24 Takeda is currently evaluating the safety and efficacy of zasocitinib in Phase 3 studies in psoriatic arthritis and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa.28-33 Zasocitinib is an investigational compound that has not been approved for use by any regulatory authority.
About Tyrosine Kinase 2 (TYK2) Inhibitors
TYK2 is a central mediator of core inflammatory pathways in psoriasis — IL-23/IL-17 axis and type I interferon signaling — making it a promising target as inhibition of a single pathway may not fully control disease for every patient.22,26,34 TYK2 is an intracellular enzyme and member of the Janus kinase (JAK) protein family.22-23 However, TYK2 is distinct from JAK1, 2 and 3 as it primarily regulates immune responses, whereas JAK1, 2 and 3 regulate broader biological processes such as lipid metabolism and hematopoiesis.22-23 Highly selective allosteric inhibition of TYK2, with minimal inhibition of JAK1, 2 and 3, is a promising therapeutic approach to target immune-mediated inflammation.27
About the Phase 3 LATITUDE PsO 3001 and 3002 Studies
The Phase 3 LATITUDE PsO 3001 (NCT06088043) and 3002 (NCT06108544) studies are global, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies to evaluate the efficacy, safety and tolerability of zasocitinib in adult patients with moderate-to-severe plaque psoriasis.6-7 The studies were conducted in 21 countries, with LATITUDE PsO 3001 enrolling 693 participants and LATITUDE PsO 3002 enrolling 1,108 participants, respectively. The co-primary endpoints were the proportion of zasocitinib-treated patients achieving sPGA 0/1 and PASI 75 response compared to placebo at week 16.6-7 Ranked secondary endpoints included comparisons versus placebo (week 16) and apremilast (week 16 and week 24).6-7
About the Phase 3 LATITUDE PsO 3003 Study
The LATITUDE PsO 3003 (NCT06550076) study is a Phase 3, multicenter, open-label study evaluating the long-term safety, tolerability and efficacy of zasocitinib in adults with moderate-to-severe plaque psoriasis.4 The study enrolled approximately 2,100 participants and consists of two parts.4 In Part A (de novo cohort), adult patients who had not been exposed to zasocitinib before received zasocitinib 30 mg once daily for up to 52 weeks.4 Patients who completed Part A or the treatment period in the Phase 3 LATITUDE PsO 3001 (NCT06088043) and 3002 (NCT06108544) studies received zasocitinib for up to 156 weeks in Part B.4 The primary endpoint was the number of zasocitinib-treated patients with treatment-emergent and serious adverse events.4 Secondary endpoints were the proportion of zasocitinib-treated patients achieving sPGA 0/1 and PASI 75 response.4
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
References:
Armstrong AW, et al. Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates efficacy at high impact sites in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002). Presented at the 2026 American Academy of Dermatology Innovation Academy. 2026 July 16; New York, NY.
Gooderham M, et al. Once-daily oral zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile in moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002). Presented at the 2026 American Academy of Dermatology Innovation Academy. 2026 July 16; New York, NY.
Mehrotra S, Sano Y, Halkowycz P, et al. Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor. J Invest Dermatol. 2026;146:214-222.e7.
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT06550076. Updated June 2, 2026. Accessed September 2026. https://clinicaltrials.gov/study/NCT06550076.
Lupulescu AM, Savu AP, Bucur Ş, et al. Hard-to-Treat Areas in
Psoriasis: An Underevaluated Part of the Disease. Life (Basel). 2025;15(3):425. Published 2025 Mar 7. doi:10.3390/life15030425.
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-Severe Plaque Psoriasis During 52 Weeks of Treatment. ClinicalTrials.gov Identifier: NCT06088043. Updated October 24, 2025. Accessed September 2026. https://clinicaltrials.gov/study/NCT06088043.
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period. ClinicalTrials.gov Identifier: NCT06108544. Updated November 20, 2025. Accessed September 2026. https://clinicaltrials.gov/study/NCT06108544.
Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in Special Localizations. Reumatologia. 2018;56(6):392-398. doi:10.5114/reum.2018.80718.
Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23.
Bhosle, MJ, Kulkarni A, et al. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;35(4). https://doi.org/10.1186/1477-7525-4-35.
Dhabale A, Nagpure S. Types of psoriasis and their effects on the immune system. Cureus. 2022 Sep 24;14(9):e29536. doi: 10.7759/cureus.29536.
Taliercio VL, Snyder AM, Webber LB, et al. The Disruptiveness of Itchiness from Psoriasis: A Qualitative Study of the Impact of a Single Symptom on Quality of Life. J Clin Aesthet Dermatol. 2021;14(6):42-48.
Snyder AM, Taliercio VL, Webber LB, et al. The Role of Pain in the Lives of Patients with Psoriasis: A Qualitative Study on an Inadequately Addressed Symptom. J Psoriasis Psoriatic Arthritis. 2022 Jan;7(1):29-34. doi: 10.1177/24755303211066928. Epub 2021 Dec 12. PMID: 39296728; PMCID: PMC11361505.
Blackstone B, Patel R, Bewley A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis (Auckl). 2022;12:25-33.doi:10.2147/PTT.S32844.
United Nations (2024). World Population Prospects 2024: Summary of Results. UN DESA/POP/2024/TR/NO. 9. New York: United Nations.
Kircher M, et al. Poster (C-048) presented at: International Society for Pharmacoepidemiology (ISPE) Annual Meeting; August 22-26, 2025; Washington, DC, USA. (ISPE_2025_Chang_Presented Poster_PsO epiOST prevalence poster).
Mehta S, Sathe NC. Plaque psoriasis. In: StatPearls. StatPearls Publishing; 2025. Accessed September 2, 2026. https://www.ncbi.nlm.nih.gov/books/NBK430879/.
Narayanan S, Guyatt V, Franceschetti A, Hautamaki EL. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl). 2014;5:1-7. Published 2014 Dec 23. doi:10.2147/PTT.S74906.
Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 221;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6.
Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1119. doi:10.1111/jdv.14868.
Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022;13(1):1–14. doi:10.4331/wjbc.v13.i1.1.
Leit S, Greenwood J, Carriero S, et al. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279. J Medicinal Chemistry.2023;66(15):10473-10496.doi.org/10.1021/acs.jmedchem.3c00600.
Mehrotra S, Sano Y, Halkowycz P, et al. Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor. J Invest Dermatol. 2026;146:214-222.e7. https://www.jidonline.org/action/showPdf?pii=S0022-202X%2825%2900531-7.
Armstrong AW, Gooderham M, Lynde C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. August 21, 2024. JAMA Dermatol. 2024 August 21;160;(10):1066- 1074. doi:10.1001/jamadermatol.2024.2701.
Shang L, et al. TYK2 in immune responses and treatment of psoriasis. J Inflamm Res. 2022;15:5373-5385. 2022 Sep 16. doi:10.2147/JIR.S38068.
Krueger JG, McInnes IB, Blauvelt A. Tyrosine Kinase 2 and Janus Kinase‒Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869.
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines. ClinicalTrials.gov Identifier: NCT06671483. Updated August 11, 2026. Accessed September 2026. https://clinicaltrials.gov/study/NCT06671483.
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines. ClinicalTrials.gov Identifier: NCT06671496. Updated August 11, 2026. Accessed September 2026. https://clinicaltrials.gov/study/NCT06671496.
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease. ClinicalTrials.gov Identifier: NCT06233461. Updated August 27, 2026. Accessed September 2026. https://clinicaltrials.gov/study/NCT06233461.
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov Identifier: NCT06254950. Updated August 17, 2026. Accessed September 2026. https://www.clinicaltrials.gov/study/NCT06254950.
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo. ClinicalTrials.gov Identifier: NCT07108283. Updated August 14, 2026. Accessed September 2026. https://clinicaltrials.gov/study/NCT07108283.
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa. ClinicalTrials.gov Identifier: NCT07244263. Updated March 6, 2026. Accessed September 2026.
Martin G. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors. Dermatol Ther (Heidelb). 2023;13(2):417-435. doi:10.1007/s13555-022-00878-9.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260914748441/en/
Permalink
https://www.aetoswire.com/en/news/1409202657284
Contacts
Investor Relations:
Christopher O’Reilly
takeda.ir.contact@takeda.com
Media Relations:
Tsuyoshi Tada (Tokyo)
toiawase_kouhou@takeda.co.jp
Jennifer Henesey (Boston)
Media_Relations@takeda.com
Tuesday, September 15, 2026
Venture Global and China Gas Announce New Long-Term LNG Agreement
ARLINGTON, Va. -
(BUSINESS WIRE) -- Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio.
"Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel.
“We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio and reinforces our commitment to establishing an international energy trading platform that connects high-quality global resources with rising energy demand worldwide.”
About Venture Global
Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing carbon capture and sequestration projects at each of its LNG facilities.
About China Gas
China Gas Holdings Limited and its subsidiaries (the “Group”) is one of China’s largest trans-regional, integrated energy suppliers and service providers. Focusing on China, it is primarily engaged in the investment, construction, and operation of city and township gas pipelines, gas terminals, storage and transportation facilities, and gas logistics systems to deliver natural gas and liquefied petroleum gas (LPG) to residential, industrial, and commercial users. The Group also builds and operates compressed natural gas (CNG)/LNG fueling stations while developing and applying natural gas and LPG technologies. At China Gas, over two decades of exploration and growth were translated into a full-fledged business portfolio centered around piped gas, stretching across LPG, LNG, smart energy services, gas equipment and kitchen appliances and grid-based new retail in the private domain backed by stores.
Forward-Looking Statements
This press release contains certain statements that may include “forward-looking statements.” All statements, other than statements of historical or present facts or conditions, included herein are “forward-looking statements.” Included among “forward-looking statements” are, among other things, statements regarding Venture Global’s business strategy, plans and objectives. Venture Global believes that the expectations reflected in these “forward-looking statements” are reasonable, however they are inherently uncertain and involve a number of risks and uncertainties beyond Venture Global’s control. In addition, assumptions may prove to be inaccurate. Actual results may differ materially from those anticipated or implied in “forward-looking statements” as a result of a variety of factors. These “forward-looking statements” speak only as of the date made, and other than as required by law, Venture Global undertakes no obligation to update or revise any “forward-looking statement” or provide reasons why actual results may differ, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260914377822/en/
Permalink
https://www.aetoswire.com/en/news/1409202657294
Contacts
Investor Contact:
Ben Nolan
IR@ventureglobalLNG.com
Media Contact:
Shaylyn Hynes
press@ventureglobalLNG.com
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications
Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs
Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography
(BUSINESS WIRE) -- According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era.
To help organizations turn this readiness into deployment, Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed.
As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryptographic agility needed to protect sensitive data, applications and digital identities.
“The risks that quantum computing poses to encryption standards are unprecedented,” said Todd Moore, VP of Data Security Products at Thales. “Enterprises need to build post-quantum readiness through cryptographic agility. Powered by our custom-designed cryptographic processor, Luna 8 delivers high-performance support for both current and post-quantum algorithms, while helping customers maintain control over security.”
“The new quantum-safe HSM from Thales enables us to support multiple secure environments while simplifying operations and making more efficient use of our infrastructure,” said Jack Zhou, CIO at HKVAX. “The flexibility to support multiple use cases, applications and business needs over time helps us maximize hardware investments. The combination of predictable performance and high availability gives our IT and security teams the assurance they need to operate efficiently to deliver consistent service to our stakeholders.”
“Integration, automation and scalability are increasingly important considerations for organizations modernizing their cryptographic infrastructure,” said Michela Menting, Vice President, Research, at ABI Research. “Luna 8 combines support for post-quantum cryptography with the flexibility organizations need to adapt as security requirements constantly evolve.”
Key advantages of the Luna 8 HSM include:
Quantum readiness: Luna 8 secures the cryptographic keys underpinning critical enterprise services such as PKI, certificate management, authentication, digital signing and identities; while providing a seamless path to post-quantum cryptography without disrupting existing investments.
Performance: With orders of magnitude faster cryptographic operations, Luna 8 delivers the performance needed for the most demanding applications.
Scalability: It scales effortlessly from enterprise deployments to hyperscale environments, supporting rapidly growing cryptographic workloads without compromise.
Future-proof: Its upgradeable architecture makes it easy to introduce new algorithms, standards, and capabilities, ensuring it remains secure, adaptable, and future-ready for years to come.
Portability: Seamless migration for existing customers as it uses the same ancillaries and interfaces without requiring changes to current applications.
Flexibility: Luna 8 is delivered on a unified hardware appliance designed to support a variety of cryptographic applications. Future releases will also support payShield 11K, extending the platform to payment HSMs that protect payment transactions, PINs and sensitive cryptographic keys used by banks and payment providers worldwide.
Luna 8 is the first next-generation HSM on the new Thales HSM platform. Available now as a network appliance, it provides quantum-safe, tamper-resistant security with scalable performance. Designed for the highest assurance requirements, Luna 8 is being independently assessed to meet some of the world’s most demanding security standards (including FIPS 140-3 Level 3 and EU Common Criteria).
Find out more about the technical specifications of Luna 8 here or join our webinar here.
Read more about Thales’ expertise in post-quantum cryptography:
Why post-quantum cryptography matters for digital identity
How to safeguard mobile connectivity in a post-quantum world
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.
The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies. Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.
Recent images of Thales and its Defense, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team.
PLEASE VISIT
Thales Group
Cybersecurity Products | Thales Group
Cybersecurity Solutions | Thales Group
View source version on businesswire.com: https://www.businesswire.com/news/home/20260804748922/en/
Permalink
https://aetoswire.com/en/news/1409202657283
Contacts
PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0) 6 60 38 48 92
marion.bonnet@thalesgroup.com
Motive Announces Entitlement Server General Availability for iPhone Duo, iPhone 18 Pro and iPhone 18 Pro Max
A launch-ready, cloud-native platform that lets operators support the latest iPhone models from day one.
(BUSINESS WIRE) -- Motive, a global leader in mobile device and connectivity management, today announced the general availability of Motive Entitlement Server support for iPhone Duo and the iPhone 18 series.
Ahead of Apple’s announcement, Motive invested in the platform capabilities needed to support the new devices at launch. As a result, operators can support the new iPhone product families without waiting for additional platform development.
The release provides comprehensive support for entitlement applications aligned with GSMA standards and interoperates with iOS and Android device ecosystems. This includes iPhone Handoff, which lets customers of supported carriers switch seamlessly between two iPhones while using a single phone number.
“Apple’s latest announcement marks another important step toward an eSIM-first future,” said Jeevithan Muttu, SVP and General Manager of Device Management at Motive. “We invest early and work closely across the device ecosystem so operators can support new experiences from day one.”
Delivering an experience such as iPhone Handoff requires more than basic device compatibility. Operators must authenticate the device, validate subscriber and service eligibility, and orchestrate activation securely in real time. Motive Entitlement Server provides this critical control layer through a cloud-native platform designed for high-volume, geo-redundant mobile environments.
This readiness allows Motive customers to move directly into testing and introduce support for the new iPhones with less operational complexity.
The eSIM-only iPhone Duo raises customer expectations even further. Service activation, transfer, and device changes must work securely and seamlessly, without a physical SIM, store visit, or support call. Motive helps operators deliver that experience while protecting subscriber identities and maintaining control throughout the activation journey.
Motive’s advanced platform capabilities, AI-driven analytics, and continuously updated device libraries give operators the intelligence needed to support new iOS, Android, and other connected devices. With a proven track record supporting major operators worldwide, Motive is recognized as a leader in Entitlement Server solutions.
“As eSIM-only devices become mainstream, the Entitlement Server becomes a strategic asset for the entire mobile experience,” added Muttu. “Operators that invest in this foundation can respond faster to device innovation, differentiate the customer experience, and unlock new opportunities for service growth.”
About Motive
Motive empowers the world’s leading telecom operators to deliver seamless digital services through its suite of operator-first platforms. From entitlement orchestration to device and service management, Motive enables operators to accelerate digital transformation and monetize connectivity across mobile, home, and IoT networks. For more information, visit www.motive.com
Apple, iPhone, iPhone 18 Pro, iPhone 18 Max, iPhone Duo and iPhone Handoff are trademarks of Apple Inc., registered in the U.S. and other countries. All other trademarks referenced herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260914881024/en/
Permalink
https://aetoswire.com/en/news/1409202657296
Contacts
Media contact:
Liberty Communications
Motive@libertycomms.com
+44 207 751 4444
Monday, September 14, 2026
Behind the Stage Lights: How Students Learned to Trust Their Voices with Doha Debates
Doha, Qatar - Monday, 14. September 2026
During high school years in Model United Nations, Dahlia Al-Ansari learned to argue on behalf of a country she was assigned to represent. But when Doha Debates invited her to join a town hall debate in Toronto this July, she faced an unfamiliar challenge: sharing her own beliefs about a timely issue.
An 18-year-old biological sciences student at Carnegie Mellon University in Qatar, Al-Ansari hadn’t traveled to defend a predetermined position. Instead, she discovered that she was there to think critically, express her own viewpoint and remain open to diverse perspectives.
This shift required her to navigate uncharted waters, but “I’m happy that it did,” she says. “It’s showing me the importance of speaking up for myself.”
Al-Ansari was among 20 students from Qatar, Canada and Mexico who spent eye-opening days preparing for the live debate. The town hall, titled “Football fandom: Community or commodity?”, explored the impact of big money on football fandom. The student group joined guests Shireen Ahmed, David Goldblatt and Kely Nascimento for a wide-ranging, thoughtful conversation about whether powerful investors have corrupted football and its fans or given the sport a global upgrade.
The town hall, a collaboration between Doha Debates and Qatar’s Years of Culture initiative, brought young people from this year’s partner countries together to engage openly with different cultures. Since 2012, Years of Culture has focused on building lasting relationships through cultural exchange.
While their preparation covered both debate techniques and football-focused discussions, many students said the most valuable outcome was learning to trust their own voice amid differing views.
For J Lina El Zeini, a Georgetown University international economics student, that realization meant overcoming self-doubt. “I struggled at the start. I was nervous, stumbled over some of my words and felt like I had messed up,” the 20-year-old Palestinian Canadian said. By the time the town hall was over, things had changed “I had not only become more confident in my public speaking, I had also realized that my voice has value, and that meaningful dialogue is something I want to keep being part of,” she said.
The students’ transformations, as it turns out, weren’t by chance, but by design. Their pre-debate journey was intentionally structured to help them manage stress, navigate differing opinions and build confidence.
For Ayaan Khan, a 20-year-old University of Toronto student, transformation was about showing up “not as someone searching for the perfect response, but as someone prepared to engage, contribute, and grow alongside others.”
By the time the students arrived at Toronto’s Terminal Theatre on July 8, they had spent days practicing how to engage across differences and speak from personal conviction. As the cameras rolled and the lights came up, they listened intently, shared their views and shed long-held conversational habits.
When her turn to speak came, Al-Ansari felt that old instinct to reach for something rehearsed but resisted. “I decided to say what I had been thinking about for the last three minutes,” she said.
El Zeini experienced a similar breakthrough. he found her stride: “The overwhelmingly good feedback I got from the audience confirmed what I want to hold onto,” she said. Speak on what you believe is right, and trust that people will meet you there.”
The whole experience translated into pure excitement for Jose Emiliano, a Mexican political science student at Carleton University in Ottawa. After the debate, when asked to rate his readiness to step outside his comfort zone on a scale of one to five, he didn’t hesitate. “A five,” he said.
The full town hall episode is now out on the Doha Debates and Al Jazeera English YouTube channels.
About
Doha Debates engages a vanguard of intellectually curious truth-seekers to constructively debate differences in order to build a better future. We emphasize unity over division, encouraging conversations that bring us together rather than drive us apart.
Doha Debates
Website: DohaDebates.com
X/Twitter: @DohaDebates
Instagram: @DohaDebates
Facebook.com/DohaDebates
YouTube.com/DohaDebates
Threads.net/@dohadebates
TikTok: @DohaDebates
Permalink
https://www.aetoswire.com/en/news/1409202657295
Contacts
Sumi Alkebsi
Director of Communications and Marketing
salkebsi@dohadebates.com
MEX Exchange, Part of MultiBank Group, Expands Executive Team as International Growth Accelerates
• Brian Liedberg joins MEX Exchange, bringing more than 30 years of experience across global capital markets, electronic trading and FinTech
(BUSINESS WIRE)--MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced the appointment of Brian Liedberg as Chief Revenue Officer and Global Head of Sales, strengthening its commercial leadership as the company continues to develop its institutional trading business and expand its presence across international markets.
Liedberg brings more than 30 years of experience across global capital markets, electronic trading and financial technology, with a career spanning institutional sales, business development, commercial strategy and revenue growth.
Prior to joining MEX Exchange, Liedberg served as Head of Global Sales and Chief Revenue Officer at TradAir, where he led the company’s global commercial growth through its acquisition by ION Group. He previously served as Head of Global Sales and Chief Business Officer at Ingenium, overseeing global sales, business development and commercialisation.
His career also includes senior leadership roles at Integral, Enigma Securities and Celer Technologies, where he worked across global sales, electronic trading, digital assets and institutional markets.
Brian Andreyko, CEO of MEX Exchange, said: “Brian Liedberg brings extensive experience across institutional markets and electronic trading, combined with a strong track record in building commercial relationships and driving international growth. His understanding of the institutional trading landscape will be valuable as we continue to develop MEX Exchange and strengthen our engagement with clients across global markets.”
The appointment further strengthens MEX Exchange’s leadership team as it continues to build its institutional capabilities and expand its presence across global electronic trading markets.
ABOUT MULTIBANK GROUP
MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives, serving over 2 million clients across 100 countries, and boasts a daily trading volume that exceeds $35 billion. Renowned for its innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group offers an array of brokerage services and asset management solutions. It is regulated across five continents by 18+ of the most reputable financial authorities globally. The group’s award-winning trading platforms offer up to 1000:1 leverage on a diverse range of products, including Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 financial awards recognizing its trading excellence and regulatory compliance. For more information, visit MultiBank Group’s http://www.multibankgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260913319267/en/
Permalink
https://www.aetoswire.com/en/news/1409202657282
Contacts
Nikolas Neofytou
MultiBank Group
nikolas.neofytou@multibankfx.com
Sunday, September 13, 2026
Last Night, a Star-studded Evening Celebrating Moncler’s Fifth Avenue Flagship Ushered in a New Chapter in the Brand’s Enduring Love Story With New York
NEW YORK -
(BUSINESS WIRE) -- Last night, on occasion of the opening of Moncler’s largest-ever global flagship on Fifth Avenue, special guests including Cher, Julia Roberts, Anne Hathaway, Serena Williams, Future, Spike Lee, Jessica Chastain, Adrien Brody, Odell Beckham Jr., Maria Sharapova, Colin Kaepernick, Adriana Lima, Mark Ronson, Shaun White, Helena Christensen, Penn Badgley, Gus Kenworthy, Jordan Clarkson, Coco Rocha, François Arnaud, Gavin Casalegno, Jacob Whiteduck-Lavoie, Sam Nivola, Evan Mock, Sammi Cheng, Princess Olympia of Greece, Hiroshi Fujiwara, Daniel Arsham, Edward Enninful, Tobe and Fat Nwigwe, Joaquín Furriel, Lucas Pinheiro Braathen, Nic von Rupp, Daniel Humm, Juliana Awad, Mickalene Thomas, Questlove, Michael Rainey Jr., Pete Davidson, and Francis Mallmann came together to mark a new chapter in the brand’s decades-long relationship with New York City.
All guests named above wore Moncler.
FIFTH AVENUE CELEBRATIONS
Moncler’s new Fifth Avenue address set the scene for a joyful evening of celebrations, dancing to live sets by DJs Mark Ronson and Carlita, accompanied by cocktails and canapés by celebrated chef Yann Nury.
THE PIONEERS DINNER AT GOTHAM HALL
Following the cocktail celebrations on Fifth Avenue, Remo Ruffini, Executive Chairman of Moncler S.p.A., hosted guests at an exclusive dinner for global pioneers from diverse disciplines at New York’s iconic Gotham Hall.
Guests were transported to an alpine forest within Gotham Hall, revisiting the setting of Moncler Grenoble’s Fall/Winter 2013 show, which famously turned the venue into an alpine landscape. The mountain-inspired three-course dinner was created by three-Michelin-starred chef Daniel Humm of New York’s acclaimed Eleven Madison Park.
Additional images of the celebrities attending the event can be downloaded at this link: https://bfa.com/events/55675/share/b14a0221e24791
View source version on businesswire.com: https://www.businesswire.com/news/home/20260904757149/en/
Permalink
https://aetoswire.com/en/news/1209202657277
Contacts
monclerpress@moncler.com
Subscribe to:
Posts (Atom)